Clinical data
ATC code none
CAS Number 686344-29-6 YesY
PubChem (CID) 10052040
ChemSpider 8227602 N
KEGG D09362 YesY
Chemical and physical data
Formula C25H25Cl2N7O
Molar mass 510.4 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]

See also


  1. Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
  2. Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
  3. http://www.pfizer.com

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.